El-Dakhakhny Amr S, El-Karamany Tarek M, El-Atrebi Mohamed, Gharib Tarek
Department of Urology, Faculty of Medicine, Benha University, Benha, Egypt.
Department of Urology, El-Sahel Teaching Hospital, Cairo, Egypt.
Arab J Urol. 2019 Apr 24;17(2):143-149. doi: 10.1080/2090598X.2019.1600993. eCollection 2019.
: To evaluate the outcome of intradetrusor onabotulinumtoxinA (Botox®; Allergan Inc., Dublin, Ireland) (IDB) injection in children and adolescents with non-neurogenic overactive bladder (OAB) refractory or resistant to treatment. : In all, 91 patients underwent evaluation using subjective scores and urodynamic studies (UDS), including determination of maximum bladder capacity (MBC) and evaluating the capacity deficit vs the expected bladder capacity (EBC), and uroflowmetry determination of voided volume, maximum urinary flow rate (Q) and post-void residual urine volume (PVR). All patients received oxybutynin (0.3-0.5 mg/kg/day) for 3 months and re-evaluated patients who developed drug intolerability, persistence or recurrence of OAB received 100 U IDB injection using 20 injection sites, with trigone and sphincter sparing. All patients were re-evaluated 3-monthly for subjective scoring and at the end of the 12-month follow-up with UDS. : In all, 43 patients underwent IDB injection and at the end of the 12-month follow-up the success rate for IDB injection was 90.7%. All patients showed progressively decreasing scores compared to baseline scores. At the 12-month follow-up, MBC, voided volume, and Q were significantly higher, whilst capacity deficit and PVR were significantly lower than baseline measures. The frequency of patients satisfied with the outcome of IDB was high. : For children with OAB refractory or resistant to biofeedback therapy, anti-cholinergic drugs must be tried first with IDB reserved for cases who fail to respond, are intolerant or recur after medical treatment. IDB using 100 U Botox, at 20 injection sites with trigone and sphincter sparing, is successful with a high satisfaction rate and free of postoperative problems. : EBC: expected bladder capacity; IDB: intradetrusor onabotulinumtoxinA; MBC: maximum bladder capacity; OAB: overactive bladder; OABSS: Overactive Bladder Symptom Score; PPBC: Patient Perception of Bladder Condition; PVR: post-void residual urine volume; TENS: transcutaneous electrical nerve stimulation; Q: maximum urinary flow rate; UDS: urodynamic studies; UI: urinary incontinence.
评估膀胱内注射A型肉毒毒素(保妥适®;爱尔兰都柏林艾尔建公司)(IDB)对难治性或治疗抵抗性非神经源性膀胱过度活动症(OAB)儿童及青少年的治疗效果。总共91例患者接受了主观评分和尿动力学检查(UDS)评估,包括测定最大膀胱容量(MBC)、评估容量不足与预期膀胱容量(EBC)的差异,以及通过尿流率测定排尿量、最大尿流率(Q)和排尿后残余尿量(PVR)。所有患者接受奥昔布宁(0.3 - 0.5mg/kg/天)治疗3个月,对出现药物不耐受、OAB持续存在或复发的患者重新评估,对这些患者采用20个注射位点、避开三角区和括约肌进行100U的IDB注射。所有患者每3个月进行一次主观评分重新评估,并在12个月随访结束时进行UDS检查。总共43例患者接受了IDB注射,在12个月随访结束时,IDB注射的成功率为90.7%。与基线评分相比,所有患者的评分均逐渐降低。在12个月随访时,MBC、排尿量和Q显著升高,而容量不足和PVR显著低于基线测量值。对IDB治疗效果满意的患者比例较高。对于难治性或治疗抵抗性生物反馈治疗的OAB儿童,必须首先尝试抗胆碱能药物,IDB仅用于治疗无效、不耐受或药物治疗后复发的病例。使用100U保妥适、20个注射位点、避开三角区和括约肌的IDB治疗成功率高,满意度高,且无术后问题。EBC:预期膀胱容量;IDB:膀胱内注射A型肉毒毒素;MBC:最大膀胱容量;OAB:膀胱过度活动症;OABSS:膀胱过度活动症症状评分;PPBC:患者对膀胱状况的感知;PVR:排尿后残余尿量;TENS:经皮电刺激神经;Q:最大尿流率;UDS:尿动力学检查;UI:尿失禁